Multinucleated tumor cells in clear cell renal cell carcinoma.


Journal

American journal of clinical pathology
ISSN: 1943-7722
Titre abrégé: Am J Clin Pathol
Pays: England
ID NLM: 0370470

Informations de publication

Date de publication:
01 Dec 2023
Historique:
received: 07 04 2023
accepted: 05 07 2023
medline: 4 12 2023
pubmed: 9 8 2023
entrez: 9 8 2023
Statut: ppublish

Résumé

Multinucleated tumor cells (MTCs) in clear cell renal cell carcinoma (ccRCC) are not well understood. Our study included ccRCC cases in a single institution between 2010 and 2019. We classified MTC as MTC with degenerative atypia (MTCD), MTC with no anaplasia (MTCNA), and MTC with anaplasia (MTCA). Clinicopathologic characteristics and outcomes were compared between MTC groups. In all, 92 of 256 people (36%) with ccRCC had MTC. People with ccRCC with MTCD and those with ccRCC but no MTC had similar clinicopathologic characteristics and outcomes. Also, MTCNA and MTCA were associated with larger tumor size, advanced pathologic tumor stage, higher World Health Organization/International Society of Urologic Pathologists nuclear grade, and higher metastatic potential (P < .001 for each parameter). Overall, MTCA was associated with an increased rate of recurrence (P = .004), higher metastatic potential (P < .001), and shorter time to metastasis (P = .033), regardless of tumor stage. Univariate Cox regression revealed MTCNA as a significant predictor of metastasis at 5 years (hazard ratio [HR], 4.171; 95% CI, 1.934-8.998); moreover, MTCA was a significant predictor of recurrence (HR, 5.723; 95% CI, 2.495-13.124), metastasis (HR, 12.024; 5.966-24.232), and death (HR, 5.661; 95% CI, 2.688-11.924) at 5 years. Although MTCD may not be relevant in tumor grading, MTCNA and MTCA are associated with adverse outcomes.

Identifiants

pubmed: 37555895
pii: 7239935
doi: 10.1093/ajcp/aqad096
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

603-611

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Richard R Pacheco (RR)

Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, US.

Busem Binboga Kurt (B)

Dana Farber Cancer Institute, Boston, MA, US.

Kemal Kosemehmetoglu (K)

Department of Pathology, Hacettepe University, Ankara, Turkiye.

Aimi T Rothrock (AT)

Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, US.

Andrea Lightle (A)

Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, US.

Mahmut Akgul (M)

Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, US.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH